Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × daratumumab × CNS × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 22 Other hematologic neoplasm 5 Lymphoid 4 Thoracic 2 Gastrointestinal 1 CNS 1 Breast 1

Conditions

Interventions

Temozolomide 94 Radiotherapy 43 Bevacizumab 29 Carboplatin 22 Irinotecan 18 Radiosurgery 16 pembrolizumab 15 Radiation 14 Nivolumab 14 Magnetic Resonance Spectroscopy 9 Cyclophosphamide 9 Trastuzumab 8 Surgical Procedures, Operative 7 Radiotherapy, Intensity-Modulated 7 Pemetrexed 7 Paclitaxel 7 Interleukin-2 7 Filgrastim 7 Erlotinib Hydrochloride 7 Carmustine 7 fludarabine 6 Specimen Handling 6 Ipilimumab 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Everolimus 6 Capecitabine 6 aldesleukin 5 Vorinostat 5 Radiotherapy, Conformal 5 Melphalan 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04922723 2025-04-18

PRIDE

West Virginia University

Phase 1/2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡